



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 48/00, C12N 5/22, 5/16, C07H 21/04 (11) International Publication Number: WO 95/10305
 A1 (43) International Publication Date: 20 April 1995 (20.04.95)

(21) International Application Number:	PCT/US94/11853	(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).
(22) International Filing Date:	17 October 1994 (17.10.94)	
(30) Priority Data:	08/138.637 15 October 1993 (15.10.93) US	
(60) Parent Application or Grant		Published
(63) Related by Continuation		With international search report.
US	138,637 (CIP)	
Filed on	15 October 1993 (15.10.93)	
(71) Applicant (for all designated States except US):	THOMAS JEFFERSON UNIVERSITY [US/US]; 1020 Locust Street, Philadelphia, PA 19107-6799 (US).	
(72) Inventors; and		
(75) Inventors/Applicants (for US only):	ZALEWSKI, Andrew [US/US]; 619 Elkins Park, Elkins Park, PA 19117 (US). SHI, Yi [CN/US]; Apartment 504, 100 Old York Road, Jenkintown, PA 19046 (US).	
(74) Agents:	NEELEY, Richard, L. et al.; Cooley Godward Castro Huddleson & Tatum, 4th floor, Five Palo Alto Square, Palo Alto, CA 94306-2155 (US).	

(54) Title: INHIBITION OF EXTRACELLULAR MATRIX SYNTHESIS BY ANTISENSE COMPOUNDS DIRECTED TO NUCLEAR PROTO-ONCOGENES

(57) Abstract

A method and compounds are provided for inhibiting the synthesis of extracellular matrix proteins. Compounds of the invention comprise antisense oligonucleotides specific for nuclear proto-oncogenes. Preferably, antisense compounds of the invention are selected from the group consisting of c-myc and c-myb and are locally administered. The invention finds use in the treatment of a variety of disorders, including sclerotic disorders and restenosis, associated with the inappropriate synthesis of extracellular matrix proteins, particularly collagen.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INHIBITION OF EXTRACELLULAR MATRIX SYNTHESIS BY ANTISENSE
COMPOUNDS DIRECTED TO NUCLEAR PROTO-ONCOGENES

5

The invention relates generally to oligonucleotides and their use as therapeutic agents, and more particularly to the use of oligonucleotide antisense and anti-gene compounds to inhibit the synthesis of extracellular matrix proteins, particularly in fibroblasts and smooth muscle cells.

10

Background

Extracellular matrix consists primarily of collagens, proteoglycans, elastin, and fibronectin. The inappropriate synthesis of extracellular matrix proteins and/or the synthesis of aberrant forms of such proteins is associated with wide range of deleterious conditions, including many rare heritable diseases as well as more commonly acquired disorders, such as fibrotic skin disease, pulmonary fibrosis, osteoarthritis, vascular restenosis, and the like, e.g., Weiss and Jayson, Editors, Collagen in Health and Disease (Churchill Livingstone, Edinburgh, 1982); Gardner, Editor, Pathological Basis of the Connective Tissue Diseases (Lea & Febiger, Philadelphia, 1992).

Many of these conditions are associated with very complex biological responses to physical, chemical, and/or biological insults. Such responses include the proliferation and migration of a variety of cell types and the synthesis of growth factors that contribute to or modify the response. For example, vascular disorders, such as atherosclerosis and vascular restenosis, are associated with local cell proliferation and migration, as well as the production of several classes of structural proteins and many growth factors, including platelet-derived growth factor, basic fibroblastic growth factor, tumor necrosis factor α , interleukin-1, prostaglandins, and a variety of proto-oncogenes, e.g., Ross, Nature, 362: 801-809 (1993); and Morishita et al, Proc. Natl. Acad. Sci., 90:8474-8478 (1993). Unfortunately, the precise role of these factors in the various disease processes is not well understood.

The tremendous economic impact of disorders associated with inappropriate production of extracellular matrix proteins, especially vascular disorders, has served as a strong impetus to develop drugs or other methods of treatment to cure or ameliorate their debilitating effects. In this class of disease, as well as others, where a disease

condition is associated with the apparent aberrant expression of a endogenous gene, the use of so called antisense compounds provides many advantages, e.g. Milligan et al, J. Med. Chem., 36:1923-1937 (1993); Uhlmann and Peyman, Chemical Reviews, 90:543-584 (1990); Goodchild, Bioconjugate Chemistry, 1:165-187 (1990); Crooke, Ann. Rev. Pharmacol. Toxicol., 32:329-376 (1992); Stein et al, Science, 261:1004-1012 (1993); and the like.

A particularly compelling advantage of the antisense approach is that one need not carry out one or more initial screening steps to identify candidate compounds capable of binding to a therapeutic target. If the aberrant expression of a gene is known to cause 10 a disease for which a drug is sought, then the structures of candidate antisense drugs are determined automatically from the nucleotide sequence of the aberrantly expressed gene. One need only provide an oligonucleotide or an analog thereof capable of forming a stable duplex or triplex with such a gene, or associated target polynucleotide, based on Watson Crick or Hoogsteen binding, respectively. The specifically bound antisense 15 compound then either renders the respective targets more susceptible to enzymatic degradation, blocks translation or processing, or otherwise blocks or inhibits the function of a target polynucleotide.

It would be highly advantageous if particular genes were identified whose expression were causally related to the synthesis of structural proteins, such as collagen, 20 that contribute to disease conditions. Such identification would immediately lead to the prospect of treatments for a number of disorders associated with the excess synthesis of such proteins by the antisense approach.

Summary of the Invention

25 The invention provides a method of treating disorders associated with the inappropriate synthesis of extracellular matrix proteins, particularly collagen. The method comprises the step of administering to an individual in need of such treatment an effective amount of one or more antisense oligonucleotides specific for nuclear proto-oncogenes. As defined more fully below, an "antisense oligonucleotide specific for 30 a nuclear proto-oncogene" is an oligonucleotide having a sequence (i) capable of forming a stable duplex with a portion of an mRNA transcript of a nuclear proto-oncogene, or (ii) capable of forming a stable triplex with a portion of a nuclear proto-oncogene.

Preferably, the antisense oligonucleotides of the invention form stable duplexes with portions of an mRNA transcript of a nuclear proto-oncogene. More preferably, antisense oligonucleotides of the invention are specific for mRNA transcripts of c-myc or c-myb proto-oncogenes. Most preferably, antisense oligonucleotides of the invention are specific for mRNA transcripts of the c-myc proto-oncogene.

Preferably, c-myc antisense oligonucleotides are administered locally to the site at which the inappropriate synthesis of extracellular matrix proteins takes place.

Brief Description of the Figures

10 FIG. 1 is a photograph of a cross-section of an exemplary control (i.e., which received sense oligomer injection) coronary artery one month following injury.

FIG. 2 is a photograph of a cross-section of an exemplary antisense-treated coronary artery.

15 FIG. 3 illustrates maximal neointimal area as a function of degree of injury.

FIG. 4 describes the effect of antisense oligonucleotides targeting the translation initiation region of *c-myc* mRNA on extracellular levels of procollagen I, procollagen III and fibronectin in post-confluent human smooth muscle cells. Procollagen I and procollagen III in conditioned medium were determined by immunoblotting, whereas fibronectin was measured by immunoprecipitation.

20 FIG. 5 describes the sequence-specific effect of *c-myc* antisense oligonucleotides on type I collagen. Smooth muscle cells were incubated with different control oligonucleotides (16 μ M) including sense, 4 bp mismatched and scrambled sequences and antisense oligonucleotides (16 μ M) targeting various regions of *c-myc* mRNA for 24 hours. The levels of type I collagen in media were measured after conditioned pepsin

25 digestion using Western blot. *Top panel:* Blots demonstrate collagen α chains. *Lane 1:* no oligonucleotides; *Lane 2:* sense oligonucleotides; *Lane 3:* 4 bp mismatched ODN; *Lane 4:* scrambled oligonucleotides; *Lane 5:* antisense targeting the translation initiation regions of *c-myc* mRNA (position 559-573, AS1); *Lane 6:* antisense targeting exon 1 (position 400-419, AS2) and *Lane 7:* antisense targeting translated region in exon 3 (position 1264-1283, AS3). *Lower panel:* Histograms depicting percent change of control values (no oligonucleotides) obtained from densitometric measurements of 3

separate experiments (mean \pm SEM). Mis: 4 bp mismatched oligonucleotides; Scr: scrambled oligonucleotides.

FIG. 6 describes the inhibition of *c-myc* protein by antisense oligonucleotides (AS1). Post-confluent smooth muscle cells were incubated with or without antisense oligonucleotides for 24 hours. The p62*c-myc* was determined by immunoprecipitation of [³⁵S]methionine-labeled nuclear extracts and it is shown on autoradiogram of SDS-polyacrylamide gel.

FIG. 7 describes metabolic state of smooth muscle cells following oligonucleotides. Cells were preincubated with or without oligonucleotides (16 μ M) for 4 hours and labeled with [³⁵S]methionine for 16 hours. The radiolabeled proteins were measured after TCA precipitation. Antisense oligonucleotides showed no effect on methionine incorporation into proteins demonstrating normal metabolic activity of smooth muscle cells. Data represent dpm/10⁵ cells (mean \pm SEM of 2 separate experiments), S: sense; MIS: mismatched; SCR: scrambled; AS1: antisense oligonucleotides targeting translation initiation region of *c-myc* mRNA.

FIG. 8 describes the recovery of type I collagen after the removal of *c-myc* antisense oligonucleotides (AS1). smooth muscle cells were incubated with or without oligonucleotides (16 μ M) for 24 hours. After 3 washes, medium without oligonucleotides was added and collected 24 hours thereafter. Type I collagen was determined by Western blot after pepsin digestion. A complete recovery of type 1 collagen is seen after the removal of *c-myc* antisense oligonucleotides.

FIG. 9 describes the effect of *c-myc* antisense oligonucleotides on pro α_1 (I) and pro α_2 (I) mRNA levels. Total RNA was isolated from smooth muscle cells incubated with or without oligonucleotides (16 μ M) for 24 hours and analyzed by Northern blot (10 μ g/lane). Antisense oligonucleotides (AS1) had no effect on procollagen α_1 (I) and procollagen α_2 (I) mRNA levels. Experiments carried out at 6 hours after antisense treatment yielded similar results. 7S RNA showed no change.

FIG. 10 describes the extracellular and intracellular [¹⁴C] proline labeled proteins. Cells were incubated with or without oligonucleotides for 16 hours, then labeled with [¹⁴C]proline for an additional 4 hours in serum-free medium. [¹⁴C]proline labeled proteins were analyzed on polyacrylamide SDS gels. The inhibition of radiolabeled proteins in

conditioned media was seen which was accompanied by an increased level of intracellular procollagen α_1 (I) and α_2 (I) following *c-myc* antisense treatment.

FIG. 11 describes the hydroxyproline content in antisense treated and control human smooth muscle cells.

5 FIG. 12 describes the effect of *c-myc* antisense treatment on extracellular collagen levels in human skin fibroblasts.

FIG. 13 describes the intracellular and extracellular procollagen level associated with *c-myc* antisense treated and control human skin fibroblasts.

10 FIG. 14 describes the thermal stability of intracellular procollagen in human skin fibroblasts. The pepsin-purified procollagen from cells treated with or without oligonucleotides was incubated with trypsin and chymotrypsin at indicated temperatures for 2 minutes and electrophoresed on polyacrylamide SDS gels. A similar melting temperature (i.e., about 41°C) was seen regardless of treatment suggesting a normal triple helical conformation of procollagen α chains after *c-myc* antisense oligonucleotides.

15 FIG. 15 describes the procollagen α_1 (I) mRNA level in *c-myc* antisense oligonucleotide treated and control human skin fibroblasts.

FIG. 16 describes the collagen I levels in *c-myc* antisense treated and control human skin fibroblast 24 hours after treatment with oligonucleotides.

20 FIG. 17 describes a cross-sectional view of a porcine coronary artery and perivascular tissues. Distribution of *c-myc* antisense oligonucleotides (Seq. ID NO: 1) was assessed within the vessel wall and in the adjacent perivascular tissues. (Magnification x 20).

FIG. 18 A-F describe the patterns of *c-myc* antisense (SEQ. ID NO: 1) ODN distribution in the coronary arteries 30 minutes following transcatheter administration.

25 *Panels A and B:* Phase-contrast and fluorescence microscopy photomicrographs of the same section demonstrating transmural localization of fluorescein-labeled oligonucleotides. Antisense oligonucleotides are present in the media, adventitia and perivascular tissues. *Panels C and D:* Phase-contrast and fluorescence microscopy photomicrographs showing subintimal, non-transmural ODN distribution. oligonucleotides are detectable only in the 30 media. *Panels E and F:* Phase-contrast and fluorescence microscopy photomicrographs exhibiting midwall, non-transmural ODN presence. (Magnification x 62.5).

FIG. 19 A and B describe the persistence of *c-myc* antisense oligonucleotides within the arterial wall 3 days following transcatheter administration. *Panels A and B:* Phase-contrast and fluorescence microscopy photomicrographs of the same section respectively. (Magnification x 62.5).

5 FIG. 20 describes a bar graph depicting vessel-associated and perivascular radioactivities following intramural administration of ^{35}S -labeled phosphorothioate *c-myc* antisense oligonucleotides. A similar total ODN content is noted at 30 min ($n=6$) and at 3 days ($n=4$) after their delivery due to ODN trafficking from the perivascular space toward the vessel wall. Results are presented as mean \pm SEM.

10 FIG. 21 A-D describe the presentation of vascular structures following transcatheter administration of *c-myc* antisense oligonucleotides. *Panel A:* fluorescence-labeled oligonucleotides are clearly visible within the coronary arterial wall at 30 minutes after injection. *Panel B:* adjacent sections demonstrate preserved internal elastic lamina and normal orientation of elastic tissues without disruption (Verhoeff stain).
15 *Panel C:* mild decrease of cytoplasmic staining and nuclear pyknosis was noted at the site of ODN retention (hematoxylin and eosin stain). *Panel D:* section adjacent to shown in FIG. 19 demonstrating resolution of the above changes 3 days after delivery of oligonucleotides (hematoxylin and eosin stain, magnification x 50).

20 FIG. 22 describes the intracellular localization of fluorescein-labeled *c-myc* antisense oligonucleotides assessed by confocal microscopy of vascular smooth muscle cells *in vitro*.

FIG. 23 describes the intracellular localization of fluorescein-label *c-myc* antisense oligonucleotides 30 minutes after intramural delivery of oligonucleotides *in vivo*, nuclear localization is visible in medial smooth muscle cells.

25 FIG. 24 describes the intracellular localization of fluorescein-label *c-myc* antisense oligonucleotides 30 minutes after intramural delivery of oligonucleotides *in vivo*, nuclear localization is visible in adventitial smooth muscle cells.

Definitions

The term "oligonucleotide" as used herein includes linear oligomers of natural or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, α -

anomeric forms thereof, polyamide nucleic acids, and the like, capable of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, Hoogsteen or reverse Hoogsteen types of base pairing, or the like. Usually monomers are linked by phosphodiester bonds 5 or analogs thereof to form oligonucleotides ranging in size from a few monomeric units, e.g. 3-4, to several hundreds of monomeric units. Whenever an oligonucleotide is represented by a sequence of letters, such as "ATGCCTG," it will be understood that the nucleotides are in 5'->3' order from left to right and that "A" denotes deoxyadenosine, 10 "C" denotes deoxycytidine, "G" denotes deoxyguanosine, and "T" denotes thymidine, unless otherwise noted. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like, as more fully described below.

As used herein, "nucleoside" includes the natural nucleosides, including 2'-deoxy and 2'-hydroxyl forms, e.g. as described in Kornberg and Baker, DNA Replication, 2nd 15 Ed. (Freeman, San Francisco, 1992). "Analogs" in reference to nucleosides includes synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g. described generally by Scheit, Nucleotide Analogs (John Wiley, New York, 1980). Such analogs include synthetic nucleosides designed to enhance binding properties, e.g. duplex or triplex stability, specificity, or the like.

"Stability" in reference to duplex or triplex formation roughly means how tightly 20 an antisense oligonucleotide binds to its intended target sequence; more precisely, it means the free energy of formation of the duplex or triplex under physiological conditions. Melting temperature under a standard set of conditions, e.g. as described below, is a convenient measure of duplex and/or triplex stability. Preferably, antisense 25 oligonucleotides of the invention are selected that have melting temperatures of at least 50°C under the standard conditions set forth below; thus, under physiological conditions and the preferred concentrations duplex or triplex formation will be substantially favored over the state in which the antisense oligonucleotide and its target are dissociated. It is understood that a stable duplex or triplex may in some embodiments include mismatches 30 between base pairs and/or among base triplets in the case of triplexes. Preferably, antisense oligonucleotides of the invention form perfectly matched duplexes and/or triplexes with their target polynucleotides.

The term "synthesis" as used herein in a biological context refers to a process involved in the production of biological molecules, in particular extracellular matrix molecules and extracellular matrix proteins. The term "synthesis" includes processes both inside and outside a cell that result in biological molecules, for example, but not limited 5 to, mRNA transcription, mRNA translation, post-translational protein modification, glycosylation, peptidase cleavage, extracellular peptidase cleavage, intra-cellular peptidase cleavage, protein transport, protein secretion and protein phosphorylation. Preferably the invention inhibits protein translation of extracellular matrix molecules, post-translational protein processing, protein secretion or intracellular peptidase cleavage.

10 The term "collagen" as used herein refers to a class of molecules which are synthesized from procollagen. Collagen is synthesized from procollagen extracellularly, by the cleavage of N- and C- termini outside the cell. Antibodies to the triple helical region of collagen can recognize the triple helical region in procollagen as well. Antibodies used herein are either specific for collagen I and procollagen I or collagen III 15 and procollagen III. Collagen can also be synthesized *in vitro* from procollagen by pepsin.

Detailed Description of the Invention

The invention relates to the use of certain antisense compounds to inhibit the 20 inappropriate synthesis in a tissue of extracellular matrix proteins, particularly collagen, and more particularly type I and type III collagen. The inappropriate and/or excessive synthesis of extracellular matrix proteins can result in medical conditions that exhibit formation of, e.g., unwanted fibrous connective tissue. Such medical conditions include sclerotic disorders, vascular restenosis, atherosclerosis, atherogenesis, keloid disease, 25 liver cirrhosis, rheumatoid disorders of the joints, post-surgical scarring, reconstructive surgery, and the like, generally found in human subjects. A range of tissue types can be the site of such inappropriate synthesis, including vascular smooth muscle cells, endothelial cells, skin and organ fibroblasts, e.g. in keloid disease or posttraumatic or postsurgical scar formation, and synovial cells and other joint components. The invention 30 is particularly useful in the treatment of restenosis, an acute vascular injury, typically following angioplasty in a human subject. Restenosis is associated with smooth muscle cell migration to the vascular intima, proliferation, and synthesis of extracellular matrix

components, e.g. Holmes et al, Chapter 12 in Vlietstra et al, Editors, PTCA (Davis Company, Philadelphia, 1987).

By administering a therapeutically effective amount of an antisense compound to a tissue having a target polynucleotide the inappropriate (i.e. excessive) synthesis of extracellular protein is inhibited. Target polynucleotides may be single stranded or double stranded DNA or RNA; however, single stranded DNA or RNA targets are preferred. The genomic nucleotide sequence and the mRNA transcripts of nuclear oncogenes of the invention are known in the art and include c-myc, c-myb, c-fos, N-myc, L-myc, p53, c-rel, c-ski, c-ets-1, c-ets-2, and the like, e.g. Glover, editor, *Oncogenes* (IRL Press, Oxford, 1989). More particularly, *c-myc* and *c-myb* sequences are described in the following references: *c-myc* proto-oncogene sequences are described in Marcu et al, *Ann. Rev. Biochem.*, 61:809-860 (1992); Watt et al, *Nature*, 303:725-728 (1983); Battey et al, *Cell*, 34:779-787 (1983); and Epstein et al, NTIS publication PB93-100576; the *c-myb* proto-oncogene is described in Gewirtz et al, U.S. patent 5,098,890 and Majello et al, *Proc. Natl. Acad. Sci.* 79:9636-9640 (1986). Preferably, the nuclear proto-oncogenes targeted by antisense oligonucleotides of the invention are *c-myc* and/or *c-myb*.

It is understood that the target to which the *c-myc* antisense oligonucleotides of the invention are directed include allelic forms of the proto-oncogenes. There is substantial guidance in the literature for selecting particular sequences for antisense oligonucleotides given a knowledge of the sequence of the target polynucleotide, e.g. Ulmann et al (cited above); Crooke (cited above); and Zamecnik and Stephenson, *Proc. Natl. Acad. Sci.*, 75: 280-284 (1974). Preferably, the sequences of *c-myc* antisense compounds are selected so that the G-C content is at least 60%. Preferred mRNA targets include the 5' cap site, tRNA primer binding site, the initiation codon site, the mRNA donor splice site, the mRNA acceptor splice site, and the like, e.g. Goodchild et al, U.S. patent 4,806,463.

When selecting antisense oligonucleotides to target the ATG intiation site of human *c-myc* in the second exon, antisense oligonucleotide with consecutive sequences can be administered using oligonucleotides 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 bases in length and selected from a twenty five base region on either side of the ATG site (sequence from Gazin et al,):

5' cccgc tccagcaggcc tccccgcgacg ATG cccctcaacg ttatgtttcac caaca 3'

Preferably antisense oligonucleotides will include the ATG site. Twenty five base regions on either side of SEQ. ID. NO: 6 and 7 may be also be used to select oligonucleotides of the size discussed in this paragraph.

5 Antisense oligonucleotides of the invention may comprise any polymeric compound capable of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-nucleoside interactions, such as Watson-Crick type of base pairing, Hoogsteen or reverse Hoogsteen types of base pairing, or the like. Antisense compounds of the invention may also contain pendent groups or moieties, either as part of or separate
10 from the basic repeat unit of the polymer, to enhance specificity, nuclease resistance, delivery, or other property related to efficacy, e.g. cholesterol moieties, duplex intercalators such as acridine, poly-L-lysine, "end capping" with one or more nuclease-resistant linkage groups such as phosphorothioate, and the like. Sequences of certain representative oligonucleotides useful in this invention are set forth in the
15 Sequence Listing included herewith.

Antisense compounds of the invention include the pharmaceutically acceptable salts thereof, including those of alkaline earths, e.g. sodium or magnesium, ammonium or NX₄⁺, wherein X is C₁-C₄ alkyl. Other pharmaceutically acceptable salts include organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic, and succinic
20 acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, and benzenesulfonic; and inorganic acids such as hydrochloric, sulfuric, phosphoric, and sulfamic acids. Pharmaceutically acceptable salts of a compound having a hydroxyl group include the anion of such compound in combination with a suitable cation such as Na⁺, NH₄⁺, or the like.

25 Preferably, nuclease resistance is conferred on the antisense compounds of the invention by providing nuclease-resistant internucleosidic linkages. Many such linkages are known in the art, e.g. phosphorothioate: Zon and Geiser, Anti-Cancer Drug Design, 6: 539-568 (1991); Stec et al, U.S. patent 5,151,510; Hirschbein, U.S. patent 5,166,387; Bergot, U.S. patent 5,183,885; phosphorodithioates: Marshall et al, Science, 30 259:1564-1570 (1993); Caruthers and Nielsen, International application PCT/US89/02293; phosphoramidates, e.g.-OP(=O)(NR¹IR²)-O- with R¹ and R² hydrogen or C₁-C₃ alkyl: Jager et al, Biochemistry, 27:7237-7246 (1988); Froehler et al,

International application PCT/US90/03138; peptide nucleic acids: Nielsen et al, Anti-cancer Drug Design, 8: 53-63 (1993), International application PCT/EP92/01220; methylphosphonates: Miller et al, U.S. patent 4,507,433, Ts'o et al, U.S. patent 4,469,863, Miller et al, U.S. patent 4,757,055; and P-chiral linkages of various types, especially phosphorothioates, Stec et al, European patent application 92301950.9 and Lesnikowski, Bioorganic Chemistry, 21:127-155 (1993). Additional nuclease linkages include phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilate, alkylphosphotriester such as methyl- and ethylphosphotriester, carbonate such as carboxymethyl ester, carbamate, morpholino carbamate, 10 3'-thioformacetal, silyl such as dialkyl (C₁-C₆)- or diphenylsilyl, sulfamate ester, and the like. Such linkages and methods for introducing them into oligonucleotides are described in many references, e.g. reviewed generally by Peyman and Ulmann (cited above); Milligan et al (cited above); Matteucci et al, International application PCT/US91/06855. Preferably, phosphorus analogs of the phosphodiester linkage are employed in the 15 compounds of the invention, such as phosphorothioate, phosphorodithioate, phosphoramidate, or methylphosphonate. More preferably, phosphorothioate is employed as the nuclease resistant linkage. It is understood that in addition to the preferred linkage groups, compounds of the invention may comprise additional modifications, e.g. boronated bases, Spielvogel et al, 5,130,302; cholesterol moieties, Shea et al, Nucleic Acids Research, 18:3777-3783 (1990) or Letsinger et al, Proc. Natl. Acad. Sci., 20 86:6553-6556 (1989); 5-propenyl modification of pyrimidines, Froehler et al, Tetrahedron Lett., 33: 5307-5310 (1992); and the like.

Preferably, antisense compounds of the invention are synthesized by conventional means on commercially available automated DNA synthesizers, e.g. an Applied 25 Biosystems (Foster City, CA) model 380B, 392 or 394 DNA/RNA synthesizer. Preferably, phosphoramidite chemistry is employed, e.g. as disclosed in the following references: Beaucage and Iyer, Tetrahedron, 48:2223-2311 (1992); Molko et al, U.S. patent 4,980,460; Koster et al, U.S. patent 4,725,677; Caruthers et al, U.S. patents 4,415,732; 4,458,066; and 4,973,679; and the like.

30 In embodiments where triplex formation is desired, there are constraints on the selection of target sequences. Generally, third strand association via Hoogsteen type of binding is most stable along homopyrimidine-homopurine tracks in a double stranded

target. Usually, base triplets form in T-A*T or C-G*C motifs (where "-" indicates Watson-Crick pairing and "*" indicates Hoogsteen type of binding); however, other motifs are also possible. For example, Hoogsteen base pairing permits parallel and antiparallel orientations between the third strand (the Hoogsteen strand) and the 5 purine-rich strand of the duplex to which the third strand binds, depending on conditions and the composition of the strands. There is extensive guidance in the literature for selecting appropriate sequences, orientation, conditions, nucleoside type (e.g. whether ribose or deoxyribose nucleosides are employed), base modifications (e.g. methylated cytosine, and the like) in order to maximize, or otherwise regulate, triplex stability as 10 desired in particular embodiments, e.g. Roberts et al, Proc. Natl. Acad. Sci., 88:9397-9401 (1991); Roberts et al, Science, 258:1463-1466 (1992); Distefano et al, Proc. Natl. Acad. Sci., 90:1179-1183 (1993); Mergny et al, Biochemistry, 30:9791-9798 (1991); Cheng et al, I. Am. Chem. Soc., 114:4465-4474 (1992); Beal and Dervan, Nucleic Acids Research, 20:2773-2776 (1992); Beal and Dervan, I. Am. Chem. Soc., 15 114:4976-4982 (1992); Giovannangeli et al, Proc. Natl. Acad. Sci., 89: 8631-8635 (1992); Moser and Dervan, Science, 238:645-650 (1987); McShan et al, J. Biol. Chem., 267:5712-5721 (1992); Yoon et al, Proc. Natl. Acad. Sci., 89:3840-3844 (1992); Blume et al, Nucleic Acids Research, 20:1777-1784 (1992); and the like.

The length of the oligonucleotide moieties is sufficiently large to ensure that 20 specific binding will take place only at the desired target polynucleotide and not at other fortuitous sites, as explained in many references, e.g. Rosenberg et al, International application PCT/US92/05305; or Szostak et al, Meth. Enzymol. 68:419-429 (1979). The upper range of the length is determined by several factors, including the inconvenience and expense of synthesizing and purifying oligomers greater than about 30-40 nucleotides 25 in length, the greater tolerance of longer oligonucleotides for mismatches than shorter oligonucleotides, whether modifications to enhance binding or specificity are present, whether duplex or triplex binding is desired, and the like. Usually, antisense compounds of the invention have lengths in the range of about 12 to 60 nucleotides. More preferably, antisense compounds of the invention have lengths in the range of about 15 30 to 40 nucleotides; and most preferably, they have lengths in the range of about 18 to 30 nucleotides.

Preferably, the thermal stability of the antisense oligonucleotides of the invention are determined by way of melting, or strand dissociation, curves. The temperature of fifty percent strand dissociation is taken as the melting temperature, T_m , which, in turn, provides a convenient measure of stability. T_m measurements are typically carried out 5 in a saline solution at neutral pH with target and antisense oligonucleotide concentrations at between about 1.0-2.0 μ M. Typical conditions are as follows: 150 mM NaCl and 10 mM MgCl₂ in a 10 mM sodium phosphate buffer (pH 7.0) or in a 10 mM Tris-HCl buffer (pH 7.0); or like conditions. Data for melting curves are accumulated by heating a sample of the antisense oligonucleotide/target polynucleotide complex from room 10 temperature to about 85-90°C. As the temperature of the sample increases, absorbance of 260 nm light is monitored at 1°C intervals, e.g. using a Cary (Australia) model 1E or a Hewlett-Packard (Palo Alto, CA) model HP 8459 UV/VIS spectrophotometer and model HP 89100A temperature controller, or like instruments. Such techniques provide a convenient means for measuring and comparing the binding strengths of antisense 15 oligonucleotides of different lengths and compositions.

Another aspect of this invention is a pharmaceutical composition useful inhibiting the synthesis of extracellular matrix proteins, comprising a pharmaceutically-acceptable excipient and an antisense oligonucleotide specific for nuclear proto-oncogene that is present in an amount sufficient to inhibit the synthesis of extracellular matrix proteins 20 when administered to a subject in need thereof. Thus, the antisense oligonucleotides of the invention are employed as one or more components of such a pharmaceutical composition. Components of pharmaceutical compositions of the invention depend on several factors, including the nature of the disease or condition being treated, the location 25 of disease lesions, the mode of drug delivery and/or administration contemplated, the latter of which can include *in vivo* administration by way of a catheter into a target lesion or organ, topical application, intranasal administration, administration by implanted or transdermal sustained release systems, and the like.

Pharmaceutical compositions of the invention include a pharmaceutical carrier that may contain a variety of components that provide a variety of functions, including 30 regulation of drug concentration, regulation of solubility, chemical stabilization, regulation of viscosity, absorption enhancement, regulation of pH, and the like. For example, in water soluble formulations the pharmaceutical composition preferably

includes a buffer such as a phosphate buffer, or other organic acid salt, preferably at a pH of between about 7 and 8. For formulations containing weakly soluble antisense compounds, microemulsions may be employed, for example by using a nonionic surfactant such as Tween 80 in an amount of 0.04-0.05% (w/v), to increase solubility.

5 Other components may include antioxidants, such as ascorbic acid, hydrophilic polymers, such as, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, dextrans, chelating agents, such as EDTA, and like components well known to those in the pharmaceutical sciences, e.g. Remington's Pharmaceutical Science, latest edition (Mack Publishing Company, Easton, PA).

10 Sustained release systems suitable for use with the pharmaceutical compositions of the invention include semi-permeable polymer matrices in the form of films, microcapsules, or the like, comprising polylactides, copolymers of L-glutamic acid and gamma-ethyl-L-glutamate, poly(2-hydroxyethyl methacrylate), and like materials, e.g. Rosenberg et al, International application PCT/US92/05305. Sustained release systems
15 also include liposomally entrapped antisense compounds, e.g. as described in Liposome Technology, Vol. II, Incorporation of Drugs, Proteins, an Genetic Material (CRC Press).

An effective amount of c-myc antisense oligonucleotide for particular applications depends on several factors, including the chemical nature of the antisense oligonucleotide, the disorder being treated, the method of administration, and the like. Preferably, an
20 effective amount will provide a concentration of c-myc antisense oligonucleotide of between about 1 to 100 μ M at the target polynucleotide; and more preferably, an effective amount will provide a concentration of antisense oligonucleotide of between about 1 to 10 μ M at the target polynucleotide.

For vascular disorders, such as restenosis, antisense oligonucleotides specific for
25 nuclear proto-oncogenes are preferably administered locally to the traumatized artery by way of a catheter. Preferably, the antisense oligonucleotides delivered to restenosis lesion are specific for c-myc and/or c-myb; more preferably, a combination of antisense oligonucleotides specific for both c-myc and c-myb is employed to reduce extracellular matrix protein synthesis associated with restenosis. Typically, restenosis occurs after a
30 procedure such as percutaneous transluminal coronary angioplasty (PTCA) which causes a local disruption or injury to an arterial wall. In response to such injury, an occlusive lesion frequently results from the following phenomena: inflammation of the of the artery

at the injury site, thrombosis, the accumulation of smooth muscles cells by migration and proliferation, and the synthesis of extracellular matrix.

For intravascular application (e.g. to prevent restenosis after angioplasty) antisense oligonucleotides are preferably administered in the vicinity of the lesion via catheter from 5 inside the lumen, or through the adventitia (i.e. the most outer layer of the vessel wall) with materials aiding a slow release of antisense compound, e.g. a pluronic gel system as described by Simons et al, *Nature*, 359:67-70 (1992) or porous balloon or iontophoretic balloon as described by Fernandez-Ortiz, A., et al., *Circulation*, 89:1518-1522 (1994), the methods of which are incorporated by reference herein. Other slow 10 release techniques for local delivery include coated stents with antisense compound, e.g. using a binder or gel, described in Wilensky et al, *Trends in Cardiovascular Med.*, 3: 163-170 (1993). A dose delivered at the target lesion is in the range of from 1 μ g to 10 mg for each or both of the antisense compounds employed in the pharmaceutical composition. Preferably the dose range is between 1 μ g and 1 mg; and more preferably, 15 the dose range is between 1 μ g and 10 μ g. Preferably, the delivery time is in the range of about 30 seconds to 60 minutes, and more preferably, in the range of about 30 seconds to about 1-2 minutes, e.g. Zalewski et al, pages 79-87 in Goldberg, editor, *Coronary Angioplasty* (Davis, Philadelphia, 1988).

For catheter administration the administered dose is in the range of .1 mg to 10 20 mg per artery, preferably .25 mg to 4 mg per artery and more preferably .5 mg to 2 mg per artery. Administered dose is the amount drug applied to the tissue, whereas "dose delivered at the target lesion" is in the amount of drug in the tissue after delivery to the tissue.

The techniques of coronary angioplasty are well known to those skilled in the art 25 and are described in detail in such comprehensive treatises as Clark, *Coronary Angioplasty* (Liss, New York, 1987), Vlietstra et al (cited above), and the like.

For excessive scar formation in the skin, e.g. postsurgical scars, keloid disease, or the like, topical or intradermal application is preferred to inhibit extracellular matrix protein synthesis, particularly collagen synthesis, by skin fibroblasts.

30 For topical application the administered dose (amount of drug applied to tissue) will generally range from .01 μ g to 10 mg of drug per cm^2 , preferably from .2 μ g to 7 mg of drug per cm^2 , and more preferably from .5 to 4 mg of drug per cm^2 .

Administered dose for use with post-surgical dressing is preferably from .2 mg to 4 mg of drug per cm². The administered dose for use with topical creams for skin abrasions, skin lesions, acne and post-surgical treatments is preferably from .05 mg to 3 mg of drug per cm².

5 For urologic disorders resulting in urethral, ureteral, or bladder scarring or narrowing, local administration via catheter or implants coated with antisense oligonucleotide is preferred.

For excessive scarring of internal organs containing smooth muscle cells and fibroblasts, such as gastrointestinal organs, biliary ducts, lungs, and liver, administration
10 of antisense compounds can be systemic or local. Local administration includes direct injection of antisense oligonucleotides into the target organ, delivery via implanted gels or polymers, or slow release from coated stents or other prosthetic materials.

For each of the disorders described above, criteria for selecting patients for treatment and means for assessing therapeutic endpoints are well known in the art
15 concerning the specific disorders. For example, in regard to vascular restenosis factors associated with susceptibility to the condition include male gender, dilation for stenosis of bypass grafts, Canadian Heart class 3 or 4 at baseline, and history of myocardial infarction, Holmes et al, Chapter 12 in Vlietstra et al, editors, PTCA (Davis Company, Philadelphia, 1987). Efficacy of treatment is assessed in the same manner as in any
20 PTCA technique. Usually, results are estimated visually, but other techniques are available. Assessment of the severity of a stenosis, or restenosis (for determining a candidate for PTCA or the results of PTCA) range from visual observation of the lesion to complex computer-based analysis of the dimensions of the artery in question, e.g. from tomographical data, flow in the distal vascular bed, densitometric characteristic of the
25 stenosis, or regional wall motion changes in the zone of the lesion, e.g. Bove, Chapter 9 in Vlietstra et al (cited above).

Example I

Inhibition of Collagen Synthesis in Human Smooth Muscles Cells

In this example, explanted human smooth muscle cells committed to collagen synthesis were treated with c-myc or c-myb antisense oligonucleotide and compared with untreated and/or "sense" treated controls.

Human smooth muscles cells (SMCs) originated from the saphenous veins of patients undergoing routine bypass surgery. The cells were isolated by an explant method. The explants were placed into tissue culture dishes containing Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% heat inactivated fetal bovine serum (FBS), 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2 mM/ml glutamine (CM-20). The cultures were maintained at 37°C in a humidified incubator with 5% CO₂. The cells exhibited typical morphological characteristics of vascular smooth muscle cells i.e., spindle shape and hill-and-valley pattern. The identification of vascular smooth muscle cells was further confirmed by *in situ* smooth muscle β-actin staining. Cells were grown to confluence and subcultured every 7 days. Only 3rd or 4th passage human smooth muscle cells were used for experiments.

The experiments were carried out in subconfluent and post confluent human smooth muscle cells. Cells were plated at 10,000/cm² (subconfluent) or 25,000/cm² (post confluent) supplemented with CM-20. Three days after plating, fresh CM-20 containing ascorbic acid (50 µg/ml) was added. The following oligonucleotides were added (16µM) to the cultures in the various experiments:

antisense (5'-AACGTTGAGG GGCAT)(SEQ ID NO: 1);
sense oligomers (5'-ATGCCCTCA ACGTT)(SEQ ID NO: 2);
25 4 bp mismatch oligomer (5'AACGTGGATT GGCAG)(SEQ ID NO: 3);
scrambled oligomer (5'-GAACGGAGAC GGTTC)(SEQ ID NO: 4);
or c-myb antisense (5'-TATGCTGTGC CGGGGTCTTC GGGC)(SEQ ID NO: 5).
Twenty four hours later, the culture medium was collected for Western blots and the cells were harvested for RNA analysis. A trypan blue exclusion assay was carried out with each experiment.

Collagen was measured as follows: Both pepsin treated (triple helical portion of collagen I) or non-pepsin treated samples were subjected to Western blot for collagen

measurement. Briefly, the samples were incubated at 4°C overnight in pepsin (1 mg/ml) and acetic acid (0.5 mol). Equal volume aliquots of samples were then concentrated in a speed vacuum centrifuge, after which samples were dissolved in SDS gel loading buffer (50mM tris • HCl pH 6.8, 100mM dithiothreitol, 2% SDS, 0.1% bromophenol blue and 5 10% glycerol) and boiled for 10 min. Following centrifugation at 11,000 g for 10 min., samples were electrophoresed through 7.5% SDS-polyacrylamide gel and transferred to nitrocellulose filter. After incubation in blocking solution, the sample-containing filters were incubated with biotin labeled primary antibody against human Collagen I and III (Southern Biotech. SC.) for 1 hour at room temperature. The filters were washed and 10 then incubated with streptavidine labeled with horseradish peroxidase. Following addition of the reaction substrate, the filters were exposed to X ray film. The experiments were repeated at least twice on separate occasions.

Human smooth muscle cells used in all experiments underwent 3-4 passages. The phenotype of these cells is considered to be irreversibly synthetic and is associated with 15 various disease states. It has been demonstrated that abnormal collagen accumulation in the vessel wall was mainly produced by these synthetic cells. Both subconfluent and postconfluent smooth muscle cells produced type I and type III collagens under serum stimulation.

In subconfluent smooth muscle cells, there was 80% reduction in collagen type 20 I synthesis after c-myc antisense oligonucleotide treatment as compared with control (no oligonucleotide added) and c-myc sense oligonucleotide treated cells. In confluent smooth muscle cells, cell numbers counted in the Coulter counter were similar among control, antisense- and sense-treated cells. Viability of cells were 97%, 96% and 95% in the control, antisense- and sense-treated cells using trypan blue exclusion assay. Collagen 25 type I was nondetectable in c-myc antisense-treated cells. Cells treated with c-myc sense oligomer showed no difference in the level of collagen type I protein as compared with control. Triple helical type I collagen was measured after digestion and the results showed the same trends with non-pepsin treated samples.

In subconfluent smooth muscle cells, there was 80% reduction in procollagen type 30 I synthesis after c-myc antisense oligonucleotide (16 µM) treatment as compared with the control (no oligonucleotide added) and c-myc sense oligonucleotide treatment. In postconfluent smooth muscle cells, collagen type I was nondetectable in c-myc antisense

treated cells. Cells treated with sense c-myc oligonucleotides and 4 bp mismatch oligonucleotides showed no reduction in the level of collagen type I protein as compared to the control (no oligonucleotide added). The reduction of collagen type I in both proliferating and postconfluent smooth muscle cells suggests that the inhibition of collagen synthesis is independent of inhibition of cell growth by antisense compounds. Different doses (4, 8, and 16 μ M) of antisense oligonucleotide produced a dose dependent reduction of procollagen type I synthesis. Cell viability following different oligonucleotide treatments was comparable, as analyzed by a trypan blue exclusion assay. More than 90% cells remained viable in all groups.

In postconfluent human smooth muscle cells, the synthesis of collagen type I was abolished by c-myb antisense oligonucleotide at a concentration of 16 μ M. In the control (no oligonucleotide) and cells treated with scrambled sequence oligonucleotides, the level of collagen type I was similar.

15

Example II

Inhibition of Collagen Synthesis in Human Skin Fibroblast Cells

In this example, explanted human skin fibroblast cells (human FBCs) were treated with c-myc or c-myb antisense oligonucleotide and compared with untreated and/or "sense" treated controls. Human FBCs were obtained from patients undergoing skin transplants and were isolated by an explant method. Explanted FBCs were cultured as described above for human smooth muscle cells and antisense and control oligonucleotides were applied in an identical manner. Human FBCs from 3rd to 10th passage cultures were used in the experiments. Collagen synthesis was measured as described in Example I.

30

In confluent human FBC, c-myc antisense oligonucleotides (8 and 16 μ M) reduced procollagen type I synthesis in a dose dependent manner. Cells treated with c-myc sense, 4 bp mismatch, or scrambled oligonucleotides showed similar levels of collagen type I protein as compared with control cells (no oligonucleotide added).

Example IIIReduction of Neointima Formation in PorcineModel of Coronary Denudation

The effectiveness of c-myc antisense compounds to inhibit neointima formation was tested by administering c-myc-specific antisense (SEQ ID NO: 1) and placebo (SEQ ID NO: 2) oligonucleotide phosphorothioates to the site of coronary angioplasty in a standard porcine model using conventional protocols, e.g. see Karas et al, J. Am. Coll. Card., 20:467-474 (1992); and Schwartz et al, Circulation, 82:2190-2200 (1990). Domestic crossbred pigs (*Sus scrofa*) were premedicated with oral aspirin (650 mg) prior to the study. General anesthesia consisted of intramuscular injection of ketamine (12 mg/kg) and xylazine (8 mg/kg). Additional doses of anesthesia were given intravenously throughout the experiment. After the right external carotid artery was surgically exposed, heparin (10,000 U) was administered to the pig intravenously, and nifedipine (10 mg) was given buccally. Using an 8 French SAL 1 guiding catheter (Medtronic Interventional Vascular, Inc., Danvers, MA) the coronary ostia were cannulated under fluoroscopic guidance. Following intracoronary injection of nitroglycerin (100 µg), and prior to the delivery of the c-myc antisense and placebo, an oversized angioplasty balloon was used to injure the intimal and medial layers of the arterial walls by inflating at 6-10 atm, according to the size of the artery which varied from 2.0 to 3.5 mm, and holding for 30 seconds three times in succession. Immediately after the angioplasty balloon was removed, intramural injections (1 mg/vessel) to the coronary arteries were carried out using a separate porous balloon. It was predetermined that intramural drug delivery was safe when the injection pressure did not exceed 4 atm, the volume of perfusate was 2 ml, and the balloon-artery ratio was about 1.4 to 1. The c-myc antisense (13 replicates) or placebo (12 replicates) oligomers were injected under 4 atm of pressure and delivery was completed in an average of 27 seconds. The dose of oligomers was 1 mg per injured coronary artery. No adverse effects were associated with the delivery of the oligomers. One month after delivery, the animals were sacrificed and the maximal neointimal area (NA max), the neointimal thickness (NT max), and the residual lumen (RL) at the injury sites were determined by morphometry. The results (mean ± SEM) are shown in Table I below:

TABLE I

Oligomer	Replicates	NA max (mm ²)	NT max (mm)	RL (%)
placebo	12	0.80 ± 0.17	0.48 ± 0.09	64 ± 6
5 antisense	13	0.24 ± 0.06	0.20 ± 0.04	81 ± 5
P		<0.01	<0.01	<0.05

FIG. 1 is a photograph of a cross-section of an exemplary control (i.e., which received sense oligomer injection) coronary artery one month following injury. A significant neointimal thickness is noted (arrows). FIG. 2 is a photograph of a cross-section of an exemplary antisense-treated coronary artery. A marked reduction of the neointima is noted. When maximal neointimal area was analyzed as a function of degree of injury (FIG. 3), regression lines representing the relationship between neointima and injury score (i.e., the severity of injury) showed a significant difference by slopes ($p < 0.01$). As shown in FIG. 3, antisense oligomers significantly reduced neointimal formation, especially with more advanced injury.

20

Example IV

Inhibition of Extracellular Matrix Production
In Human Smooth Muscle Cells By c-myc Antisense Oligonucleotide Treatment

This example further demonstrates the effectiveness of c-myc antisense oligonucleotide treatment to inhibit the synthesis of extracellular matrix protein by human smooth muscle cells, in particular procollagen I and III. Antisense treatment greatly reduced extracellular procollagen levels in stimulated human smooth muscle cells (treated with 20% FBS).

A. Measurement of procollagen I and procollagen III by Western blot.

To further determine that c-myc antisense oligonucleotides inhibited the synthesis of extracellular matrix proteins, procollagen I & III was measured from human smooth muscle cells.

Both intracellular and extracellular procollagen (both type I & III) were measured using Western blots. Resting human smooth muscle cells were maintained in medium (Dulbecco's modified eagle's medium) with .5% FBS (fetal bovine serum). Human smooth muscle cells were stimulated with or without oligonucleotides in medium 5 containing 20% FBS and ascorbic acid (50 µg/ml). FBS is known to stimulate procollagen synthesis in human smooth muscle cells. At 20 hours after the addition of oligonucleotides cells were washed threes times with phosphate-buffered saline (PBS) and serum-free medium containing 0.1% BSA, ascorbic acid and oligonucleotides was added to the culture for an additional 4 hours. The conditioned medium (medium exposed to 10 cells and oligonucleotides) was collected and proteinase inhibitors including phenylmethylsulfonyl fluoride (PMSF, 0.5 mM), pepstatin (1 µg/ml) and leupeptin (1 µg/ml) were added. The corresponding cell layer was washed three times with cold PBS and lysed in SDS-PAGE sample buffer containing 62.5 mM Tris-HCl, pH 6.8. 20% glycerol, 2% SDS, 5% β-mercaptoethanol for 30 minutes at 4°C. Cell lysates were then 15 boiled for 5 minutes to inactivate proteinases and the supernatants were collected after centrifugation at 10,000 rpm for 10 minutes at 4°C. In selected experiments, cells were continuously incubated with oligonucleotides in 20% FBS-DMEM for 24 hours and samples of culture medium were then subjected to the overnight pepsin digestion (0.1 mg/ml) in 0.5 M acetic acid at 4°C. Individual samples were concentrated 10 fold by 20 centrifugation through a Microcon-30 column (Amicon, Beverly, MA) and stored at -20°C. Aliquots were electrophoresed on 65 (w/v) polyacrylamide-SDS gels with 4% stacking regions. The fractionated proteins were then electrotransferred onto PolyScreen PVDF membranes (DuPont NEN, MA) in a transfer buffer containing 192 mM glycine, 25 mM Tris, 0.01% SDS, and 20% methanol. The blots were blocked in 5% non-fat 25 milk and incubated with antibodies against type I collagen (biotin-labeled polyclonal antibody, Southern Biotechnology Associates, Inc. AL) and against type III collagen (Gibco BRL, Gaithersburg, MD) in 2.5% BSA. The membranes were washed 3 times with PBST (PBS containing 0.1% Tween 20) and incubated with biotinylated secondary antibodies (for type III). The blots were washed and then incubated with streptavidin- 30 peroxidase conjugate (Boehringer Mannheim, Germany) for 30 minutes. After washing, the blots were incubated with Renaissance chemiluminescence reagent (DuPont NEN, MA) for 10 seconds and exposed to Kodak X-Omat film for 30 seconds to 2 minutes.

Resulting fluographs were analyzed by laser densitometry (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ).

c-myc antisense oligonucleotides corresponding to SEQ. ID. NO:1 were used in all examples, unless otherwise indicated.

5 *B. Inhibition of the Extracellular Procollagen I and Procollagen III Secretion By c-myc Antisense Oligonucleotides*

Procollagen levels were determined in post-confluent i.e., density-arrested smooth muscle cells in order to minimize the influence of various growth rates among experimental subgroups. A marked reduction (90%) of extracellular procollagen I and 10 extracellular procollagen III in the conditioned medium was observed following *c-myc* antisense oligonucleotides treatment as shown by Western blot (FIG. 4). This effect was concentration-dependent in a range of 4 - 16 μ M and it occurred as early as 3 hours following incubation of smooth muscle cells with *c-myc* antisense oligonucleotides (data not shown).

15 The reduction in extracellular procollagen I after antisense oligonucleotides was unaffected by the addition of β -aminopropionitrile excluding the possibility that antisense promoted cross-linking of collagen (data not shown).

16 *C. c-myc Antisense Phosphorothioate Oligonucleotides To Exons 1, 2 And 3 Are Effective Inhibitors Of The Synthesis Of Extracellular Matrix Proteins.*

20 To further confirm a sequence-specific action of *c-myc* antisense phosphorothioate oligonucleotides, smooth muscle cells were treated with several control sequences including sense, 4 bp-mismatched and scrambled oligonucleotides (phosphorothioate oligonucleotides are used herein unless otherwise indicated). Their effects on procollagen I levels in the conditioned medium were compared with those after three antisense 25 sequences directed against different regions of *c-myc* mRNA. As shown in FIG. 5, a consistent reduction in extracellular procollagen I was observed after treatment with different antisense oligonucleotides, whereas control sequences were devoid of such effect.

TABLE III

	<u>SEQ. ID. NO.</u>	<u>OLIGONUCLEOTIDE SEQUENCE (5'→3')</u>	<u>HUMAN c-myc NUCLEO- TIDE LOCATION;</u>	<u>OLIGONUCLEOTIDE TYPE</u>
5	1	AACGTTGAGG GGCAT	559-573;	Antisense
	2	ATGCCCTCA ACGTT	559-573;	Antisense
	3	AACGTGGATT GGCAG	559-573;	Antisense four base mismatch
	4	GAACGGAGAC GGTTC		Scrambled
	5	TATGCTGTGC CGGGGTCTTC GGGC	c-myb;	Antisense
	6	GGGAGAGTCG CGTCCTTGCT	400-419;	Antisense
	10	TCATGGAGCA CCAGGGGCTC	1264-2383;	Antisense

D. *Immunoprecipitation of Extracellular Fibronectin and Nuclear c-myc Protein*

To determine the effects of oligonucleotides sequences on protein synthesis of extracellular fibronectin and *c-myc* protein, post-confluent smooth muscle cells were 15 incubated with or without oligonucleotides in methionine-free medium for 4 hours. Afterwards, [³⁵S]methionine (25 μCi/ml, DuPont NEN, MA) was added for 16 hours and the cell number was counted in a Coulter counter. Extracellular fibronectin in the conditioned medium and *c-myc* protein in cell nuclear extracts were measured by immunoprecipitation following metabolic labeling.

The conditioned medium was collected after the addition of proteinase inhibitors and aliquots containing equal counters were incubated with antibodies against fibronectin (Becton Dickinson, Bedford, MA) for 4 hours followed by *Staphylococcus* protein A acrylamide beads for an additional 2 hours. After centrifugation, pellets were washed three times, boiled in SDS-PAGE sample buffer for 5 minutes and electrophoresed on a 20 6% polyacrylamide-SDS gel. The labeled cell layers were washed three times with cold PBS after labeling and lysed in 0.1% NP-40, 10mM Tris (pH 7.9), 10mM MgCl₂, 15 mM NaCl, 5 mM EDTA, 1 mM PMSF, 1 μg/ml leupeptin and 1 μg/ml pepstatin.

In parallel to the extracellular fibronectin assays, cell nuclei were extracted through centrifugation by procedures unknown in the art. The protein concentration in 30 nuclear extracts was measured and aliquots containing 500 μg of protein were incubated with anti-*c-myc* antibody, pan-myc, (gift from G.I. Evan), for 12 hours and then with *Staphylococcus* protein A acrylamide beads for an additional 90 minutes. After washing,

the beads were collected and boiled in SDS-PAGE sample buffer and the soluble fraction was electrophoresed on SDS-PAGE. The gel was dried and exposed to Kodak-Omat film at -70°C for 5-7 days.

5 *E. Levels of Extracellular Fibronectin Were Unchanged By c-myc Antisense Oligonucleotides, While c-myc Protein Levels Decreased*

In contrast to a significant reduction in extracellular procollagens, the levels of extracellular fibronectin in the conditioned medium were not significantly affected (FIG. 4) pointing to selective effects of antisense oligonucleotides. The incubation of post-confluent smooth muscle cells with *c-myc* antisense oligonucleotides (16 μM) resulted 10 in downregulation of *c-myc* protein in nuclear extracts (FIG. 6).

Example V

c-myc Antisense Oligonucleotides Do Not Alter Human Smooth Muscle Cell Overall Metabolism

15 To further ensure that oligonucleotides did not produce other changes in smooth muscle cell function, assays of cell membrane integrity, cell metabolism and induction of genes related to collagen synthesis or degradation pathways were conducted.

20 Human smooth muscle cells were assayed for cell membrane integrity using trypan blue. More than 95% of cells remained viable following treatment with various oligonucleotides (16 μM) as assessed by trypan blue exclusion.

25 To determine total protein synthesis aliquots of the conditioned media were precipitated in cold 10% trichloroacetic acid (TCA) for 30 minutes at 4°C and pellets were washed twice in 5% TCA. The pellets were then dissolved in Solvable™ (DuPont NEN, MA) and the incorporated radioactivity was measured in a scintillation counter (Pharmacia LKB Biotechnology Inc. Piscataway, NJ). The overall protein synthesis, as measured by [³⁵S]methionine incorporation as discussed herein, was comparable in smooth muscle cells incubated with or without antisense (SEQ. ID. NO:1) oligonucleotides (FIG. 7). Note that cells stimulated with 20% FBS showed increased protein synthesis compared to unstimulated cells treated with only .5% FBS. *c-myc* antisense 30 oligonucleotide treatment did not reduce protein synthesis compared to sense, mismatch and no oligonucleotide controls.

In addition, the level of procollagen I in the conditioned medium was restored to control levels 24 hours after the removal of *c-myc* antisense oligonucleotides (FIG. 8). These results indicated that antisense (SEQ. ID. NO:1) oligonucleotides produced a selective but reversible reduction of extracellular procollagens preserving normal 5 metabolic activity of vascular smooth muscle cells.

Because antisense oligonucleotides may induce expression of non-targeted genes, the collagenolytic activity and interferon- γ levels following treatment with *c-myc* antisense oligonucleotides was determined to exclude these non-specific effects.

Post-confluent smooth muscle cells were incubated with serum-free medium with 10 or without oligonucleotides. The aliquots of medium were collected 24 hours thereafter. Matrix metalloproteinase activities were determined after selective destruction of tissue inhibitor of metalloproteinase by dithiothritol and iodoacetamide. Latent collagenases produced by human smooth muscle cells were activated with aminophenylmercuric acetate, and then incubated with type I collagen or gelatin and cleavage products assessed 15 by SDS-PAGE (the methods of D.D. Dean, et al., J. Clin. Invest., 84:678-685 (1989) and P.E. Desrochers, et al., J. Biol. Chem. 267:5005-5012 (1992) are incorporated by reference herein). Metalloproteinases were characterized by SDS-substrate gel electrophoresis (i.e., zymography) under nondenaturing conditions using either β -casein or gelatin as substrates. Comparable collagenolytic activity against type I collagen and 20 gelatin were exhibited in conditioned medium from control, sense- and antisense- (SEQ. ID. NO:1) treated smooth muscle cells (data not shown), suggesting that *c-myc* antisense oligonucleotides did not increase endogenous collagenolytic activity.

To determine whether *c-myc* interferon- γ , a potent inhibitor of type I collagen synthesis, was inadvertently induced, interferon- γ was assayed in the culture medium and 25 human smooth muscle cells. Interferon- γ was undetectable in the conditioned culture media and cell lysates after incubation with *c-myc* antisense (SEQ. ID. NO:1) oligonucleotides using ELISA method.

Example VI

No Effect Of *c-myc* Antisense Oligonucleotides On Procollagen α_1 (I), α_2 (I) and α_1 (III) mRNAs In Human Smooth Muscle Cells

This example demonstrates that *c-myc* antisense oligonucleotide treatment does not
5 decrease the mRNA of procollagens in human smooth muscle cells.

To measure mRNA from procollagen post-confluent smooth muscle cells were
incubated with or without oligonucleotides for 24 hours, washed three times with cold
PBS and lysed in 4 M guanidinium isothiocyanate. Total RNA was isolated by phenol-
chloroform extraction followed by isopropanol precipitation. The total RNA was
10 quantitated by spectrophotometric absorbance at 260 nm. Equal amounts of RNA
samples (10 μ g) were denatured and separated on 0.8% agarose/formaldehyde gels and
blotted onto nitrocellulose membranes. The RNA was crosslinked to nitrocellulose
membranes using a UV crosslinker (Stratagene, CA). The blots were hybridized at 42°C
for 24 hours with human procollagen α_1 (I) (ATCC) and human procollagen α_2 (I) (gift
15 from H. Kuivaniemi) cDNA probes. The probe for 7S ribosomal RNA were used as
control. The probes were labeled with 32 P-CTP by nick translation to a specific activity
of greater than 10^8 cpm/ μ g DNA. The blots were sequentially washed twice in 2x, 1x,
0.5x and 0.1x SSC-0.1% SDS at 42°C for 15 min. Each wash was repeated twice. Blots
were exposed to Kodak-Omat film at -70°C with an intensifying screen for 6 hours to 3
20 days.

Downregulation of *c-myc* protein after antisense treatment raises the possibility of
transcriptional regulation of collagen expression. Accordingly, procollagen α_1 (I) and
procollagen α_2 (I) mRNA levels were analyzed in smooth muscle cells after their
incubation with or without oligonucleotides using Northern blot analysis. As shown in
25 FIG. 9, antisense oligonucleotides did not affect procollagen α_1 (I) and procollagen α_2 (I)
mRNA levels. Likewise, similar levels of procollagen α_1 (III) mRNA were seen with or
without *c-myc* antisense oligonucleotides (data not shown). 7S RNA remained unchanged
in all three experimental conditions.

Example VIIIntracellular Accumulation Of Procollagen In Human Smooth Muscle Cells
Treated With *c-myc* Antisense Oligonucleotides

This example demonstrates that *c-myc* antisense oligonucleotide treatment increases 5 procollagen inside human smooth muscle cells. These results are consistent with the decrease in extracellular matrix procollagen synthesis in the presence of *c-myc* antisense oligonucleotides.

A. *Intracellular Procollagen Levels Are Increased by *c-myc* Antisense Treatment.*

To examine mechanisms involved in the reduction of extracellular procollagen by 10 *c-myc* antisense oligonucleotides, the secreted and intracellular procollagens were determined following 4 hours of [¹⁴C]proline labeling.

To measure intracellular procollagen after *c-myc* antisense oligonucleotide treatments, cells were incubated with or without oligonucleotides for 20 hours in 20% FBS-DMEM. Serum-free medium containing ascorbic acid (50 µg/ml), [¹⁴C]proline (2.5 15 µCi/ml, DuPont NEN, MA) and oligonucleotides were added to the cells for the additional 4 hours. The culture medium was collected and proteinase inhibitors were added. Aliquots of media were centrifuged through Microcon-30 column in order to remove unincorporated radioisotope and to concentrate samples for electrophoresis. The corresponding cell layers were then washed 3 times with cold PBS, lysed in PAGE-SDS 20 sample buffer and boiled for 5 minutes to inactivate proteinases. The aliquots of concentrated medium, cell lysates (from equal cell number) and procollagen I purified from human skin fibroblast cells (gift from W. Arnold) were electrophoresed on 6% polyacrylamide-SDS gels with 3% stacking regions. The gels were fixed for 30 minutes in 10% acetic acid, 20% methanol, dried and exposed to film at -70°C for 7 days.

25 *c-myc* antisense treatment decreased in secreted [¹⁴C] proline labeled procollagen and was similar to the Western blot DNA. *c-myc* antisense treatment significantly increased the intracellular concentration of procollagen I compared to untreated cells and cells treated with a scrambled oligonucleotide (FIG. 10).

B. *The Increase In Intracellular Procollagen Level Is Not Due To The Inability Of Human Smooth Muscle Cells To Hydroxylate Proline After c-myc Antisense Oligonucleotide Treatment.*

5 The intracellular accumulation of procollagen may reflect the inhibition of post-translational modifications required for the assembly of procollagen α chains into a triple-helical conformation. Therefore, to rule out this possibility, the affects *c-myc* antisense treatment of prolyl 4-hydroxylase activity and hydroxyproline content were measured.

10 Post-confluent smooth muscle cells were incubated with or without oligonucleotides in 20% FBS-DMEM for 24 hours as described above. Cell layers were washed with cold PBS 3 times and lysed in 0.2 M NaCl, 20 mM Tris-HCl, pH 7.4, 0.1% Triton X-100, 0.1 M glycine and 10 μ M DTT (the methods of K.J. Kivirikko, et al., Methods in Enzymology, 82:245-364 (1982) are incorporated by reference herein). The lysates were then sonicated for 30 seconds on ice and protein concentration was measured. The remaining cell lysates were centrifuged at 13,000 rpm for 20 minutes at 15 4°C.

20 The aliquots of supernatant were assayed for prolyl 4-hydroxylase activity by measuring the formation of radioactive 4-hydroxyproline using a [14 C] proline-labeled procollagen I as substrate (the methods of K.J. Kivirikko, et al., Anal. Biochem., 19:249-255 (1967) are incorporated by reference herein). The aliquots of cell lysate were hydrolyzed, hydroxyproline was assayed by a specific chemical procedure.

25 Prolyl 4-hydroxylase activity, a pivotal enzyme controlling triple helix formation, was similar among experimental subgroups. It was 11.7 ± 0.1 (dpm/ μ g protein, mean \pm SD of 2 separate experiments) in control smooth muscle cells treated with no oligonucleotides, 12.1 ± 2.3 in cells incubated with scrambled oligonucleotides (16 μ M) and 10.5 ± 2.0 after treatment with *c-myc* antisense oligonucleotides (16 μ M).

Hydroxyproline content was greater in *c-myc* antisense (SEQ ID NO:1) cells than in untreated or scrambled oligonucleotide treated cells (FIG. 11). The increase in hydroxyproline content reflects the increase in procollagen levels, which is a substrate for prolyl 4-hydroxylase.

5

Example VIII

Inhibition of Extracellular Matrix Production
in Human Fibroblasts Human Skin Fibroblasts Cells
Using *c-myc* Antisense Oligonucleotides

This example further demonstrates the effectiveness of *c-myc* antisense 10 oligonucleotide treatment to inhibit the synthesis of extracellular matrix protein by human skin fibroblast cell, in particular procollagen I and III. Antisense treatment greatly reduced extracellular procollagen levels in stimulated human skin fibroblast cells (treated with 20% FBS).

A. *Assay of Extracellular and Intracellular collagen I and III Using Western Blots*
15 To further determine whether *c-myc* antisense oligonucleotides inhibited the synthesis of extracellular and intracellular procollagen I and III in human skin fibroblasts, procollagen levels were determined, as discussed for human smooth muscle cells in Example IV and VII. Human skin fibroblasts cells used in the human skin fibroblast experiments were confluent. Cells were obtained and cultured as in Example II and by 20 methods known in the art.

B. *Rapid Inhibition of Extracellular Collagen I and III Secretion By *c-myc* Antisense Oligonucleotide Treatment*
25 These experiments show that *c-myc* antisense oligonucleotides inhibit the secretion of extracellular collagen I and III by human skin fibroblasts in a dose-dependent, antisense sequence dependent manner and with a rapid time course of inhibition.

To further determine the dose response and antisense specificity of *c-myc* antisense oligonucleotides for inhibition of extracellular matrix production, extracellular collagen I was measured using Western blots of human fibroblast cell protein isolated from human fibroblasts subjected to different treatments. Human fibroblast cells were exposed to 30 either scrambled oligonucleotides (SEQ ID NO:4; 16 μ M), mismatched oligonucleotides (SEQ ID NO:3; 16 μ M), antisense oligonucleotides (SEQ ID NO:1; 4, 8 and 16 μ M) or no oligonucleotides for 24 hours as discussed herein and the proteins of those cells were

assayed for collagen I in the Western blot shown in FIG. 12, lanes 1-5, respectively. The double band reflects collagen $\alpha_1(I)$ and $\alpha_2(I)$ chains, upper and lower bands, respectively. Antisense treated cells showed a proportional decrease of the amount of collagen I with increasing levels of *c-myc* antisense oligonucleotide, while the control treatments (no treatment scrambled and mismatch) showed higher amounts of collagen than the lowest concentration of *c-myc* antisense oligonucleotide used. These results taken together with the other results discussed herein, especially the lack of up regulation of collagen and procollagen degradation pathways by *c-myc* antisense treatment, show that extracellular matrix production, in particular procollagen I secretion is inhibited by *c-myc* antisense treatments.

The time course of *c-myc* antisense oligonucleotide treatment of human skin fibroblast cell collagen I secretion showed rapid inhibition of secretion of de novo synthesized collagen I. At time zero human skin fibroblast cells were exposed to fresh medium (as used herein "fresh medium" is medium containing 20% FBS and ascorbic acid 50 μ g/ml and other components as indicated) with either no oligonucleotides, scrambled oligonucleotides, or antisense oligonucleotides for 24 hours (concentration of the oligonucleotides was 16 μ M; SEQ ID NOS: 1 and 3). At three, six and twenty four hours aliquots of each cell medium were taken and assayed for the presence of collagen I by Western blot, as discussed herein. A reduction in collagen I level was observed in 15 the antisense treated cells compared to the control cells (untreated and scrambled treated) in as early as three hours. At twenty four hours the antisense treated cells showed at least 5 to 10 times less secreted collagen I than the control cells. The six hour value produced intermediate results.

The secretion of collagen III by human fibroblast cells was also inhibited by *c-myc* 25 antisense oligonucleotides. Human fibroblast cells were treated with fresh medium containing either no oligonucleotides, 16 μ M scrambled oligonucleotides or 16 μ M *c-myc* antisense oligonucleotides for twenty four hours and the medium was assayed for the presence of extracellular collagen III at the end of the twenty four hours. No extracellular collagen III was observed in the antisense treated cells, while the control 30 cells (no treatment and scrambled treated) showed the presence of extracellular collagen III (at least 10-100 times higher level of collagen III, as compared to the antisense treated cells).

Thus, these results taken together with the other results discussed herein, show that extracellular matrix production, in particular procollagen I and III secretion, is inhibited by *c-myc* antisense treatments.

5 C. *Accumulation Of Intracellular Procollagen I And Simultaneous Decrease In Extracellular Procollagen I By c-myc Antisense Oligonucleotide Treatment*

Inhibition of procollagen secretion by *c-myc* antisense treatment of human fibroblast cells was associated with an accumulation of intracellular procollagen I. Human fibroblast cells were treated with fresh medium containing either no oligonucleotides, 16 μ M scrambled oligonucleotides, or 16 μ M *c-myc* antisense 10 oligonucleotides for twenty four hours and the medium and the corresponding human fibroblast cells were assayed for the presence of extracellular procollagen I and intracellular procollagen I using 14 C proline labelled protein synthesis products separated as discussed herein. In FIG. 13, the major bands in lanes 1-3 show procollagen $\alpha_1(I, III)$ and $\alpha_2(I)$ chains. The amount of secreted procollagen I is reduced at least 10-20 times 15 in the antisense treated cells compared to the control cells (no treatment, scrambled treated, lanes 1 and 2, respectively). The upper band in lanes 1-3 is approximately 116 Kd ("upper band"), which corresponds to procollagen $\alpha_1(I, III)$; the lower band in lanes 1-3 (from left to right) is approximately 100 Kd, which corresponds to $\alpha_2(I)$. In FIG. 13, lanes 4-6 show intracellular procollagen I is at least five times greater in antisense treated 20 cells (lane 6) than the control cells (lanes 4 and 5). In FIG. 13, lane 7 shows the molecular weight markers.

Thus, these results demonstrate that *c-myc* antisense treatment decreases the amount of procollagen secreted by human fibroblast cells and increases the amount of procollagen in the cells.

25

Example IX

c-myc Antisense Oligonucleotides Did Not Change The Thermal Stability Of Intracellular Procollagen In Human Skin Fibroblasts

The tertiary structure of intracellular procollagen was not changed by *c-myc* 30 antisense treatment. Human fibroblast cells were treated with fresh medium containing either no oligonucleotides, 16 μ M scrambled oligonucleotides, or 16 μ M *c-myc* antisense oligonucleotides for twenty four hours. The melting temperature of procollagen from

each experimental condition was measured as discussed herein and known in the art. FIG. 14 shows that the melting profile for control cells (untreated and scrambled treated) and antisense treated are similar. These results demonstrate that the procollagen present inside of antisense treated cells maintains a normal triple-helical conformation that is the same as in control treated cells.

Thus, *c-myc* antisense treatment does not lead to a detectable alteration of procollagen structure that could lead to increased intracellular degradation or decreased protein export from the cell.

10

Example X

c-myc Antisense Oligonucleotide Treatment Did Not Change The Procollagen $\alpha_1(I)$ mRNA Level In Human Skin Fibroblasts

This example demonstrates that *c-myc* antisense oligonucleotide treatment does not inhibit the synthesis of extracellular matrix protein by human skin fibroblast cells, in particular procollagen I, by reducing the mRNA level of procollagen. Antisense treatment did not reduce mRNA procollagen levels in stimulated human skin fibroblast cells (treated with 20% FBS).

A. *Measurement of Procollagen $\alpha_1(I)$ mRNA*

RNA was isolated and Northern analysis was carried out as follows: Cells were washed three times with cold PBS buffer and lysed in 4 M guanidinium isothiocyanate. RNA was extracted by phenol/chloroform and quantitated by spectrophotometric absorbance at 260/280 nm. RNA samples (20 μ g) were separated by electrophoresis on 0.8% agarose-formaldehyde gels. Following transfer of the RNA to nitrocellulose filters, blots were fixed by ultraviolet irradiation. The blots were prehybridized in 5x standard saline citrate, 2x Denhardt's solution, 0.1% SDS and 0.2mg/ml of denatured salmon sperm DNA for at least 4 hours at 65°C. Hybridization was performed overnight using the same buffer containing cDNAs radio labeled with 32 P dCTP by nick translation to a specific activity of approximately 108-109 cpm/ μ g. Blots were washed at 65°C in 0.5x standard saline citrate and 0.1% SDS. The filters were exposed to Kodak X-Omat film at -70°C with intensifying screens for 1-5 days. The autoradiography of the resulting Northern blots was quantitated by scanning densitometry and integration of peak areas. The probes used for this study were as follows: a 1.8 Kb pro-alpha 1(1) (HF-677) cDNA

corresponding to the COOH-terminal propeptide and the carboxy-terminal portion of the triple helical region of human pro-alpha 1(1) chain of type I procollagen (Chu et al., Nucleic Acids Res. 10:5925-5934, 1982).

B. *Procollagen $\alpha_1(I)$ mRNA Levels Are Not Decreased By c-myc Antisense Treatment*

5 The mRNA level of procollagen alpha I in human fibroblast cells was unaffected by *c-myc* antisense treatment. Human fibroblast cells were treated with fresh medium containing either no oligonucleotides, 16 μ M scrambled oligonucleotides, or 16 μ M *c-myc* antisense oligonucleotides for twenty four hours. mRNA was purified from each 10 experimental condition and analyzed for the presence of procollagen alpha I mRNA, as discussed herein and known in the art. FIG. 15 shows that control cell procollagen I mRNA (untreated and scrambled treated; lanes 1 and 2, respectively) levels are similar to the antisense treated cell procollagen alpha I mRNA levels (lane 3). These results demonstrate that *c-myc* antisense treatment of human fibroblast cells does not down regulate mRNA transcription of the procollagen alpha I gene.

15 Thus, taken together with the other results discussed herein, the mRNA results show that *c-myc* antisense treatment decreases the secretion of procollagen I and III, which are proteins that lead to the synthesis of collagen in the extracellular matrix.

20

Example XI

c-myc Antisense Oligonucleotides Did Not Alter The Recovery Of The Synthesis Of Extracellular Matrix Protein After the Cessation Of *c-myc* Antisense Oligonucleotide Treatment of Human Skin Fibroblasts

The ability of human fibroblast cells to synthesize collagen I after removal of 25 *c-myc* antisense oligonucleotide treatment was not impaired. Human fibroblast cells were treated with fresh medium containing either no oligonucleotides, 16 μ M scrambled oligonucleotides, or 16 μ M *c-myc* antisense oligonucleotides for twenty four hours. Human fibroblast cells from each experimental condition were then exposed to fresh 30 medium without any oligonucleotide additions and assayed for the presence of extracellular collagen I, as discussed herein. FIG. 16 shows that control cells (untreated and scrambled pretreated) and antisense treated cells produced similar levels of extracellular collagen I twenty four hours after abatement of the treatment. These results

demonstrate that after twenty four hours there was full recovery of collagen production in *c-myc* antisense treated human fibroblast cells.

Thus, *c-myc* antisense treatment did not produce any cytotoxic effects that resulted in the inability of the cell to return to pretreatment secretion levels of procollagen.

5

Example XII

Inhibition of Synthesis of Extracellular Matrix In Pig Coronary Arteries

This example further demonstrates the *in vivo* effectiveness of localized *c-myc* antisense oligonucleotide treatment to decrease the progression of extracellular matrix synthesis after tissue trauma. This example also further demonstrates the *in vivo* effectiveness of *c-myc* antisense treatment in decreasing the progression of internal organ scaring, as well as decreasing the progression of tissue scaring associated with the synthesis of extracellular matrix molecules, such as collagen.

15 A. *Inhibition of The Production of Extracellular Matrix Fibrillar Material By c-myc Antisense Oligonucleotide Treatment*

To determine the effects of *c-myc* antisense treatment on the progression of extracellular matrix synthesis after tissue trauma, pig hearts were injured *in vivo*, treated with oligonucleotides as discussed in Example III (unless otherwise indicated), and 20 sacrificed at three days, seven days, and twenty eight days after the delivery of oligonucleotides. The same *c-myc* antisense and sense oligonucleotides (SEQ ID NO: 1 and 2) and dosages (1 mg per artery) were used as in Example III.

Cross-sections of traumatized (injured) coronaries from antisense treated pigs showed differences in microscopic extracellular architecture compared to the sense treated 25 traumatized coronaries. Traumatized coronaries from each experimental group were examined as blind samples with light microscopy, magnification 20-62X. Tissue was stained with Verhoff-Van-Gieson stain, as known in the art, to highlight cells and extracellular matrix, and sirus red stain, as known in the art, to highlight collagen. The *c-myc* antisense treated vessels, which displayed a smaller neointima area compared to 30 control vessels, also displayed less red staining than the control vessels (sense treated). The antisense treated coronaries showed less extracellular fibrillar material compared to the sense treated coronaries; and the antisense treated coronaries showed less extracellular

space between cells. Neointimal smooth muscle cell proliferation was also assessed using immunostaining for PCNA (Proliferating Cell Nuclear Antigen) following balloon denudation and transcatheter delivery of *c-myc* sense (S) or antisense (AS) oligonucleotides (1 mg) into porcine coronary arteries, see Table IV. Antisense treatment 5 of coronaries inhibited the progression of smooth muscle cell proliferation caused by tissue trauma compared to sense treatment of coronaries. PCNA staining permitted the assessment of the number of proliferating cells in a given neointima cross-section. Generally 200-1,000 cells were counted and the percentage of proliferating smooth muscle cells determined and expressed as the proliferative index. The proliferative index (PI), 10 neointima/media (I/M) ratio and the reduction in I/M ratio (Δ I/M) were as follows:

TABLE IV

Day	R _x	n	P*(%)	I/M ratio	Δ I/M(%)
15	3 S	4	5±2	0.09±0.03	
	3 AS	8	3±5	0.05±0.02	↓44
	7 S	4	47±13	0.28±0.04	
	7 AS	8	11±13**	0.12±0.05**	↓57
20	28 S	6	N/A	1.19±0.51	
	28 AS	4	N/A	0.47±0.30*	↓61

P* - proliferating cells/total number of cells x 100, *p<0.05, **p<0.01

20

Coronaries with a reduction of the I/M ratio have an improved luminal diameter. These results demonstrate that localized *c-myc* antisense treatment inhibits smooth muscle cell growth and extracellular matrix formation over time.

Thus, localized *c-myc* antisense treatment inhibits the progression of scar 25 formation in a traumatized tissue, such as scar formation in coronaries after balloon angioplasty trauma caused by smooth muscle cell proliferation and extracellular matrix formation.

Example XIII

Rapid Localization c-myc Antisense Oligonucleotides In Pig Coronary Arteries

This example demonstrates the *in vivo* effectiveness of c-myc antisense oligonucleotides in penetrating vascular and connective tissues using local delivery devices. In conjunction with the other results discussed herein, these results demonstrate the ability of c-myc antisense treatment to localize in cell nuclei within 30 minutes and before the onset of c-myc induction (which occurs over three to four hours). The local distribution of c-myc antisense oligonucleotides after local administration to the vessel wall of coronary arteries decreases scar formation following balloon angioplasty.

A. *Local Delivery Of c-myc Antisense Oligonucleotides Labelled With Either Carboxyfluorscein Or ³⁵S Phosphothioate*

The c-myc antisense oligonucleotides used in this Example were prepared as discussed herein. Phosphorothioate antisense oligonucleotides (SEQ. ID NO:1) directed against the translation initiation region of the human c-myc gene used in the distribution studies labeled with carboxyfluorescins (480 nm excitation, 520 nm emission, Molecular Probes, Inc.) as previously described in Iverson, et al, Antisense Res. Dev. 2: 211-222 (1992), the methods of which are herein incorporated by reference. For the quantitative studies oligonucleotides were ³⁵S-labeled at each internucleotide link with the specific activity of 1.8×10^8 cpm/ μ mol.

Domestic crossbred pigs (*Sus scrofa*) were used and prepared for experiments as discussed herein. A coronary ostia was canulated using a 9 French SAL 1 guiding catheter (Cordis Corp., Miami, FL) was under fluoroscopic guidance. After intracoronary injection of nitroglycerin (100 μ g), a baseline coronary angiography was obtained. Selected portions of the coronary arteries were then subjected to denudation (traumatization) with an oversized balloon inflated 3 times (6 atm) for 30 sec. Then, the delivery device, a Kaplan-Simpson Infusasleeve (of LocalMed, Palo Alto, CA) was advanced over a standard angioplasty balloon ("support" balloon) to the region of interest. This device consists of multilumen infusion region (18 mm) containing multiple sideholes (40 μ m) which are juxtaposed against the vessel wall by inflating a support balloon. The device used in studies infuses solutions using rigid, noncollapsible channels. This design minimizes drug loss to the bloodstream and permits separate control of drug

infusion and placement of the drug delivery device in the vessel. After a full expansion of the internal balloon catheter, the infusion portion was fluoroscopically ascertained, c-myc antisense oligonucleotides were administered. Intramural injections were carried out under 100 PSI of the external pressure. The total volume of the injectate was 5-6 ml.

5 delivered by the external pump at 40 ml/min. The administered dose was 1 mg per artery. After injection was completed, devices were removed and final angiograms were recorded. To verify proper conditions of oligonucleotides delivery, serial quantitative coronary angiography was employed to measure the initial luminal diameter of selected coronary arteries, luminal diameter prior to oligonucleotides delivery (i.e., after denuding

10 injury) and after oligonucleotides administration. In addition, diameters of denudation and support balloons were measured *in situ*. Guiding catheter was used as a scaling device for all angiographic measurements. At the indicated times, the animals were given a lethal dose of sodium pentobarbital (100 mg/kg iv).

As shown in Table V, mean luminal vessel diameter was 2.5 ± 0.1 mm at baseline. The coronary arterial injury was produced with the oversized balloon (also known as denuding) (mean balloon:artery ratio 1.1). All vessels remained patent following balloon overstretch with mean luminal diameter of 2.6 ± 0.1 mm. C-myc antisense oligonucleotides were administered through expanded delivery device achieving direct contact with the endoluminal surface or the vessel (mean balloon:artery ratio 1.0).

20

Table V.
Angiographic Characteristics Based On Quantitative Coronary Angiography (n=14).

	Initial luminal diameter (mm)	2.5 ± 0.1
25	Denuding balloon/artery ratio	1.1 ± 0.0
	Post-denudation luminal diameter (mm)	2.6 ± 0.1
	Delivery balloon/artery ratio	1.0 ± 0.0
	Post-delivery luminal diameter (mm)	2.6 ± 0.1

B. *Qualitative Assessment of oligonucleotides Delivery:*

To determine distribution of fluorescent-labeled oligonucleotides after transcatheter delivery, the coronary arteries were excised with adjacent tissues. After the vessel lumen 5 was flushed with PBS, the arteries were fixed in 10% buffered formalin for 6 hours and embedded in paraffin. The arteries were cut into serial 4- μ m-thick sections (50 mm per vessel including 18 mm injected portion. The examination of the site of injection as well 10 as proximal and distal portions of the vessel provided information regarding the longitudinal oligonucleotides distribution. In addition, noninjected coronary artery from the same animal served as the additional control. The sections were deparaffinized and 15 covered with SlowFade-Light antifade reagent (Molecular Probes, Inc., Eugene, OR). Each slide contained the vessel, periadventitial tissue and adjacent myocardium (FIG. 17) which allowed to determine the depth of oligonucleotide penetration. The fluorescent-labeled antisense oligonucleotides were visualized under Nikon Optiphot microscope equipped for epifluorescence with XF-22 filter. Photographs were taken on Kodak Ektachrome P1600 films.

To analyze intracellular localization of fluorescent labeled oligonucleotides *in vitro* and *in vivo*, laser scanning confocal microscope (model Zeiss Axiovert 100) adapted with MRC-600 krypton-argon laser (Bio-Rad) was used. The krypton-argon laser emits laser 20 lines at excitation wavelength 488 nm. The induced fluorescent light is scanned through a 63x objective and converted to a video signal for display on a computer screen. The images were photographed off the computer screen on Kodak Ektachrome 100 films. For *in vitro* studies, in order to determine the time course of oligonucleotides uptake by vascular smooth muscle cells, cells were grown on chamber slides in medium containing 25 10% fetal bovine serum for 2 days and fluorescein-labeled oligonucleotides were added (8 μ M) for 2, 30 minutes and 2 hours. Then, cells were washed 3 times with PBS and fixed in 50% acetone and 50% methanol. For *in vivo* studies, sections of the coronary arteries obtained as described above were analyzed by confocal microscopy at 0.4 - 0.5 μ m optical thickness.

C. *Distribution Of Antisense Oligonucleotides In The Vessel Wall*

To determine oligonucleotide distribution in the arterial wall, their localization in the coronary arteries was examined at 30 minutes and 3 days after intramural

administration ($n=4$). Fluorescein-labeled oligonucleotides were detected only in the region of injection but not in distal segments or in non-injected coronary arteries. At 30 minutes, three distinct focal patterns of oligonucleotides distribution were noted within injected segments which had previously undergone balloon denudation. Dense *transmural* 5 localization involving the entire thickness of media was associated with more sparse adventitial and perivascular distribution (FIGS. 18A and 18B). In each section, oligonucleotides occupied only the portion of the arterial circumference. *Subintimal nontransmural* pattern was common; it was either interspersed between transmural localization or at the edges of injected segments (FIGS. 18C and 18D). *Midwall* 10 *nontransmural* pattern was the least common and it was found adjacent to transmural localization (FIGS. 18E and 18F). The vessel adventitia was devoid of antisense oligonucleotides in sections exhibiting nontransmural distribution.

The role of preceding vascular damage in *c-myc* antisense oligonucleotide distribution in the arterial wall was also examined. The analysis of consecutive slides 15 revealed that transmural distribution was the most common in the areas of dissection with oligonucleotide localization extending to immediately adjacent sections. The subintimal nontransmural pattern was usually associated with preserved vascular integrity. At 3 days, oligonucleotides were clearly visible in transmural localization (FIGs. 19A and 19B). The subintimal nontransmural distribution was less evident likely as a result of 20 oligonucleotides washout. No evidence for linear "jet-like" localization was present either at 30 minutes or 3 days.

These data collectively point to a focal pattern of intramural distribution of oligonucleotides after pressure-driven transcatheter administration. Coronary artery dissection due to prior balloon denudation appeared to facilitate the entry and transmural 25 distribution of oligonucleotides. The nontransmural pattern was often associated with the intact internal elastic lamina.

D. *Intramural Trafficking Of Oligonucleotides In Coronary Arteries*

The residence time of oligonucleotides *in situ* was measured to determine if antisense treatment led to oligonucleotide retention. Accordingly, to quantitatively 30 address this issue, ^{35}S -labeled *c-myc* antisense oligonucleotides were delivered using a transcatheter in porcine coronary arteries. As shown in FIG. 20, at 30 min following site-specific administration, tissue radioactivity was measured which reflects an

oligonucleotide content of 2510 ± 1436 cpm ($n=6$) in the vessel wall and 2163 ± 966 cpm ($n=6$) in the perivascular tissue as opposed to tissue background of 17 ± 4 cpm. Three days later, oligonucleotide-associated radioactivity increased to 3595 ± 1672 cpm ($n=4$) in the vessel wall, whereas in the periadventitial tissue levels decreased to 432 ± 201 cpm ($n=4$). The above sustained level of oligonucleotides was achieved despite a rapid plasma clearance ($t_{1/2} 15 \pm 2$ min). The amount of detected oligonucleotides both at 30 min and 3 days corresponded to about 0.1% of total administered dose. These results indicate that pressure-driven transcatheter delivery leads to antisense oligonucleotides deposition in medial, and adventitial tissues, as well as, perivascular tissues.

10 *E. Vascular Integrity After Intramural Administration of oligonucleotides*

Since pressure-driven transcatheter injection of any therapeutic agent to the arterial wall may induce vascular damage the extent of damage was measured. *First*, using qualitative coronary angiography, non-flow limiting coronary dissection was observed in 15 1 out of 14 intramural injections in porcine coronary arteries notwithstanding prior injury with the oversized balloon. *Second*, we have utilized quantitative coronary angiography to assess luminal diameter following intramural oligonucleotides delivery ($n=14$). There was no significant change in luminal diameter after transcatheter oligonucleotides administration (Table V). *Third*, we have assessed the effects of transcatheter 20 oligonucleotides injection using light microscopy. To this end, sections of coronary arteries with transmural distribution of oligonucleotides and no visible dissection were evaluated in order to determine subtle changes in cellular and extracellular matrix components of the vessel wall. As shown in FIG. 21, transmural distribution of oligonucleotides (FIG. 21A) was associated with the intact internal elastic lamina and 25 elastic tissues throughout the vessel wall (FIG. 21B). A mild decrease in cytoplasmic staining and nuclear pyknosis was occasionally noted at the site of oligonucleotides retention at 30 min (FIG. 21C). These changes were not found at 3 days after the delivery (FIG. 21D).

Example XIVRapid Nuclear Localization of c-myc AntisenseOligonucleotides In *in vitro* and *In Vivo* Human Smooth Muscle Cells

This example further demonstrates the effectiveness of c-myc antisense oligonucleotide treatment *in vivo* by showing the rapid localization of c-myc antisense oligonucleotides in the nuclei of human smooth muscle cells both *in vitro* and *in vivo*. This time course allows for inhibition of c-myc gene activation, previously established on the order of hours (3 to 4 hours).

10 A. Intracellular Localization Of Carboxyfluoroscein labelled c-myc Antisense Oligonucleotides

To analyze intracellular localization of fluorescent labeled oligonucleotides *in vitro*, laser scanning confocal microscope (model Zeiss Axiovert 100) adapted with MRC-600 krypton-argon laser (Bio-Rad) was used. The krypton-argon laser emits laser lines at excitation wavelength 488 nm. The induced fluorescent light is scanned through 15 a 63x objective and converted to a video signal for display on a computer screen. The images were photographed off the computer screen on Kodak Ektachrome 100 films. For *in vitro* studies, in order to determine the time course of oligonucleotides uptake by vascular smooth muscle cells, cells were grown on chamber slides in medium containing 10% fetal bovine serum for 2 days and fluorescein-labeled oligonucleotides were added 20 (8 μ M) for 2, 30 minutes and 2 hours. Then, cells were washed 3 times with PBS and fixed in 50% acetone and 50% methanol.

B. *Cellular Uptake of Antisense oligonucleotides*

The intramural delivery of antisense oligonucleotides should be followed by a rapid cellular uptake of oligonucleotides in order to permit the inhibition of expression 25 of targeted gene, in this case *c-myc*. As illustrated on FIG. 22, vascular smooth muscle cells demonstrate *in vitro* preferential nuclear localization of fluorescence 30 min following the onset of incubation with fluorescein-labeled oligonucleotides. Likewise, at 30 min following *in vivo* transcatheter administration, nuclear localization of oligonucleotides was noted within the media (FIG. 23) and the adventitia (FIG. 24) which 30 demonstrates comparably rapid uptake of antisense oligonucleotides *in vivo*. Accordingly, intracellular uptake of antisense oligonucleotides by vascular smooth muscle cells *in vitro* and *in vivo* occurs during a critical time window available for the modulation of *c-myc*.

proto-oncogene, an important inducible gene regulating smooth muscle cells proliferation following vessel wall injury.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Yi Shi and Andrew Zalewski

5 (ii) TITLE OF INVENTION: Inhibition of extracellular
matrix synthesis by antisense compounds directed to
nuclear proto-oncogenes

(iii) NUMBER OF SEQUENCES: 7

10 (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Tom M. Moran
(B) STREET: Five Palo Alto Square
(C) CITY: Palo Alto
(D) STATE: California
15 (E) COUNTRY: USA
(F) ZIP: 94306

(v) COMPUTER READABLE FORM:

20 (A) MEDIUM TYPE: 5.25 inch diskette
(B) COMPUTER: IBM compatible
(C) OPERATING SYSTEM: Windows 3.1/DOS 5.0
(D) SOFTWARE: Microsoft Word for Windows,
vers. 2.0

25 (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

30 (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

35 (A) NAME: Tom M. Moran
(B) REGISTRATION NUMBER: 26,314
(C) REFERENCE/DOCKET NUMBER: LYNX-014/00US

(ix) TELECOMMUNICATION INFORMATION:

40 (A) TELEPHONE: (415) 843-5000
(B) TELEFAX: (415) 857-0663

(2) INFORMATION FOR SEQ ID NO: 1:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

AACGTTGAGG GGCAT

15

(2) INFORMATION FOR SEQ ID NO: 2:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

ATGCCCTCA ACGTT

15

25 (2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
30 (A) LENGTH: 15 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

35 AACGTGGATT GGCAG

15

40 (2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
45 (A) LENGTH: 15 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GAACGGAGAC GGTTT

15

55 (2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TATGCTGTGC CGGGGTCTTC GGGC

24

5 (2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 nucleotides
(B) TYPE: nucleic acid
10 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

15 GGGAGAGTCG CGTCCTTGCT

20

(2) INFORMATION FOR SEQ ID NO: 7:

- 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

TCATGGAGCA CCAGGGGCTC

20

We claim:

1. A method of inhibiting the synthesis of extracellular matrix proteins in a tissue comprising administering to the tissue a therapeutically effective amount of one or more antisense oligonucleotides each specific for a nuclear proto-oncogene.
2. The method of claim 1 wherein said nuclear proto-oncogene is selected from the group consisting of c-myc, c-myb, c-Fos, N-myc, L-myc, p53, c-rel, c-ski, c-ets-1, and c-ets-2.
10
3. The method of claim 2 wherein said nuclear proto-oncogene is selected from the group consisting of c-myc and c-myb and said extracellular matrix proteins are selected from the group consisting of collagen.
- 15 4. The method of claim 3 wherein said tissue is an arterial wall.
5. The method of claim 4 wherein said step of administering includes administering said antisense oligonucleotide locally with a catheter or a coated stent.
- 20 6. The method of claim 5 wherein said one or more antisense oligonucleotides consists of an antisense oligonucleotide specific for c-myc and an antisense oligonucleotide specific for c-myb.
7. The method of claim 6 wherein said one or more antisense oligonucleotides
25 specific for said nuclear proto-oncogene are phosphorothioate oligonucleotides.
8. The method of claim 2 wherein said tissue comprises skin fibroblasts.
9. The method of claim 8 wherein said nuclear proto-oncogene is selected from the
30 group consisting of c-myc and c-myb.
10. The method of claim 9 wherein said antisense compound is administered topically.

11. The method of claim 2 wherein said tissue comprises an internal organ containing smooth muscle cells or fibroblasts.
12. The method of claim 11 wherein said nuclear proto-oncogene is selected from the 5 group consisting of c-myc and c-myb.
13. A method of treating sclerotic disorders comprising the step of administering an effective amount of an antisense oligonucleotide specific for c-myc.
- 10 14. A method of inhibiting collagen synthesis in restenosis, the method comprising the steps of locally administering an effective amount of an antisense oligonucleotide specific for c-myc.
- 15 15. The method of claim 14 wherein said step of locally administering includes administering with a catheter or a coated stent.
16. The method of claim 15 wherein said step of locally administering includes locally administering in combination an antisense oligonucleotide specific for c-myc and an antisense oligonucleotide specific for c-myb.
- 20 17. The method of claim 1 wherein said synthesis of extracellular matrix proteins is secretion of extracellular matrix proteins.
- 25 18. The method of claim 17 wherein said extracellular matrix proteins is either procollagen I or procollagen III.
19. The method of claim 1 wherein said tissue is either intima, media, or adventitia.
20. The method of claim 1 wherein said tissue is connective tissue.
- 30 21. The method of claim 1 wherein said nuclear oncogene is c-myc.

22. The method of claim 21 wherein said tissue is human connective tissue.
23. The method of claim 22 wherein said tissue comprises human fibroblasts.
- 5 24. The method of claim 21 wherein said tissue comprises human smooth muscle cells.
25. The method of claim 22 wherein said administering comprises local delivery using a catheter.
- 10 26. The method of claim 25 wherein said administering comprises local delivery using a rigid, noncollapsible channel.
- 15 27. The method of claim 25 wherein said administering comprises using iontophoresis to release said antisense oligonucleotide.
28. The method of claim 21 wherein said administering comprises using a biodegradable polymer, non-biodegradable polymer or stent to release said antisense oligonucleotide.
- 20 29. The method of claim 1 wherein said inhibiting of synthesis occurs in the absence of a biological process selected from the group consisting of down regulation of transcription of genes encoding extracellular matrix procollagen I and procollagen III, down regulation of mRNA translation of extracellular matrix procollagen I and procollagen III, up regulation of degradation intracellular pathways for extracellular matrix procollagen I and procollagen III precursors, and up regulation of degradation of extracellular matrix procollagen I and procollagen III.
- 25 30. A method of reducing scar formation in a tissue comprising: administering to said tissue a therapeutically effective amount of a proto-oncogene antisense oligonucleotide.

31. A method of claim 30 wherein said reducing of scar formation comprises decreasing the progression of extracellular matrix protein formation.
32. A pharmaceutical composition useful for inhibiting the synthesis of extracellular matrix proteins, which composition comprises a pharmaceutically-acceptable excipient and an antisense oligonucleotide specific for a nuclear proto-oncogene that is present in an amount sufficient to inhibit the synthesis of extracellular matrix proteins when administered to a subject in need thereof.
- 10 33. The composition of claim 32 wherein said antisense oligonucleotide is specific for a nuclear proto-oncogene is *c-myc*, *c-myb*, *c-Fos*, *N-myc*, *L-myc*, *p53*, *c-rel*, *c-ski*, *c-ets 1*, and *c-ets 2*.
- 15 34. The composition of claim 32 wherein said antisense oligonucleotide is chosen from the group of nucleotides consisting of Sequence ID numbers 1, 5, 6 and 7.
35. The method of claim 1 wherein said antisense oligonucleotide is chosen from the group of nucleotides consisting of Sequence ID numbers 1, 5, 6 and 7.

WG 25/10505

PCD/US94/11853

1/23



FIG. I

RECTIFIED SHEET (RULE 91)

2/23



FIG. 2

3/23




FIG. 3

4/23




FIG. 4

5/23




FIG. 5

6/23




FIG. 6




FIG. 8

7/23




FIG. 7

8/23




FIG. 9

9/23




FIG. 10




FIG. 11

10/23

SCRAMBLED (16 μ M)MISMATCHED (16 μ M)ANTISENSE (4 μ M)ANTISENSE (8 μ M)ANTISENSE (16 μ M)

NO ODNS

FIG. 12

11/23




FIG. 13

12/23




FIG. 14

13/23




FIG. 15




FIG. 16

14/23




FIG. 17

15/23

FIG. 18A




FIG. 18B

RECTIFIED SHEET (RULE 91)

16/23




FIG. 18C




FIG. 18D

17/23




FIG. 18E




FIG. 18F

RECTIFIED SHEET (RULE 91)

18/23




FIG. 19A




FIG. 19B

RECTIFIED SHEET (RULE 91)

19/23




FIG. 20




Fig. 21B

21/23



FIG. 2IC



FIG. 2ID

22/23




FIG. 22




FIG. 23

23/23




FIG. 24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/11853

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 48/00; C12N 5/22, 5/16; C07H 21/04
US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : US CL.: 514/44; 536/24.3, 23.1, 24.31, 24.1; 935/62; 435/172.3, 240.2; 604/20, 607/03

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
GENBANK, APS, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	Nature, Vol. 359, issued 03 September 1992, Simons et al, "Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo," pages 67-70, see the entire document.	1-5, 7, 17-22, 24-26 28-35 6, 16
X Y	NTIS Publication PB93-100576, issued 01 January 1993, Epstein et al., "Inhibition of Cell Proliferation Using Antisense Oligonucleotides," pages 1-38, see entire document.	1-5, 7, 11-15, 17-22, 24-26, 28-35 6, 16

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance		
E earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

13 JANUARY 1995

Date of mailing of the international search report

JAN 23 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

JACQUELINE M. STONE

Faximile No. (703) 305-3230

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/11853

A. CLASSIFICATION OF SUBJECT MATTER
US CL.:

US CL.: 514/44; 536/24.3, 23.1, 24.31, 24.1; 935/62, 435/172.3, 240.2, 604/20, 607/03

